Boston Scientific (NYSE:BSX) is planning a fourth building at its Maple, Grove, Minn. campus to support expanded nitinol stent manufacturing.
The Maple Grove Planning Commission is scheduled to review project plans tonight for the roughly 76,000 ft2 building.
“Subject to city approval, we hope to begin construction on a new building on our Maple Grove campus later this year to improve our operating performance and meet anticipated market needs,” Boston Scientific said in a statement that spokesperson Kate Haranis shared with MassDevice.
“This new building will allow for movement of some production currently taking place in existing buildings on that campus, and support increased needs for growing product lines such as the Watchman left atrial appendage closure device, Eluvia drug-eluting vascular stent system and Innova stent system.”
Documents attached to the local planning commission agenda say the new building will include equipment for blasting, electro-polishing, swaging and dimensional inspection. Moving the stent manufacturing will allow for more spacing of equipment and materials — and free up existing production space for future product creation.
The new two-story building will also include shell office space for future needs, according to the documents. There are no immediate plans to increase employment as a result of the project.
Marlborough, Mass.–based Boston Scientific has a significant presence around Minneapolis-St. Paul, with another major campus in Arden Hills and roughly 7,500 employees in Minnesota.
Update with additional information from Boston Scientific.
